Change search
ReferencesLink to record
Permanent link

Direct link
Long-Term Oxygen Therapy 24 vs 15 h/day and Mortality in Chronic Obstructive Pulmonary Disease
Lund Univ, Div Resp Med & Allergol, Dept Clin Sci, Lund, Sweden.
Univ Orebro, Sch Med Sci, Dept Resp Med, Orebro, Sweden.
Uppsala University, Disciplinary Domain of Humanities and Social Sciences, Faculty of Social Sciences, Department of Statistics.
Lund Univ, Div Resp Med & Allergol, Dept Clin Sci, Lund, Sweden.
2016 (English)In: PLoS ONE, ISSN 1932-6203, E-ISSN 1932-6203, Vol. 11, no 9, e0163293Article in journal (Refereed) Published
Abstract [en]

Long-term oxygen therapy (LTOT) >= 15 h/day improves survival in hypoxemic chronic obstructive pulmonary disease ( COPD). LTOT 24 h/day is often recommended but may pose an unnecessary burden with no clear survival benefit compared with LTOT 15 h/day. The aim was to test the hypothesis that LTOT 24 h/day decreases all-cause, respiratory, and cardiovascular mortality compared to LTOT 15 h/day in hypoxemic COPD. This was a prospective, observational, population-based study of COPD patients starting LTOT between October 1, 2005 and June 30, 2009 in Sweden. Overall and cause-specific mortality was analyzed using Cox and Fine-Gray regression, controlling for age, sex, prescribed oxygen dose, PaO2 (air), PaCO2 (air), Forced Expiratory Volume in one second (FEV1), WHO performance status, body mass index, comorbidity, and oral glucocorticoids. A total of 2,249 included patients were included with a median follow-up of 1.1 years (interquartile range, 0.6-2.1). 1,129 (50%) patients died and no patient was lost to follow-up. Higher LTOT duration analyzed as a continuous variable was not associated with any change in mortality rate (hazard ratio [HR] 1.00; (95% confidence interval [CI], 0.98 to 1.02) per 1 h/day increase above 15 h/day. LTOT exactly 24 h/day was prescribed in 539 (24%) patients and LTOT 15-16 h/day in 1,231 (55%) patients. Mortality was similar between the groups for all-cause, respiratory and cardiovascular mortality. In hypoxemic COPD, LTOT 24 h/day was not associated with a survival benefit compared with treatment 15-16 h/day. A design for a registry-based randomized trial (R-RCT) is proposed.

Place, publisher, year, edition, pages
2016. Vol. 11, no 9, e0163293
National Category
Respiratory Medicine and Allergy
Identifiers
URN: urn:nbn:se:uu:diva-304980DOI: 10.1371/journal.pone.0163293ISI: 000383892100076PubMedID: 27649490OAI: oai:DiVA.org:uu-304980DiVA: diva2:1034219
Funder
Swedish Society of MedicineSwedish Heart Lung Foundation
Available from: 2016-10-11 Created: 2016-10-11 Last updated: 2016-10-27Bibliographically approved

Open Access in DiVA

fulltext(820 kB)20 downloads
File information
File name FULLTEXT01.pdfFile size 820 kBChecksum SHA-512
7cbbaec304c27a980a455cedd635512f851d357d9e95f10d6734ea8b3f522b86e3a6412addc98ff81462a6783baf1a8c9a325ced5de3709b5dc25c443020972e
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Bornefalk-Hermansson, Anna
By organisation
Department of Statistics
In the same journal
PLoS ONE
Respiratory Medicine and Allergy

Search outside of DiVA

GoogleGoogle Scholar
Total: 20 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 69 hits
ReferencesLink to record
Permanent link

Direct link